title: Predicting improvement in signs and symptoms of plaque psoriasis after 1 week of treatment with clobetasol propionate 0.05% spray.
abstract: One of the hurdles to effectively managing plaque psoriasis is lack of adherence to prescribed treatments. Up to 40% of subjects report they do not adhere to their medication for a variety of reasons. Earlier response to treatment may be a motivator for subjects to better adhere to treatment. Clobetasol propionate 0.05% spray (CPS) is a highly potent topical corticosteroid indicated for the treatment of moderate to severe plaque psoriasis that has efficacy as early as 1 week after initiating therapy. Using data from the 2 CPS pivotal trials, a post hoc analysis was performed to determine the relationship between week 1 improvements and week 4 treatment success (defined as a score of 0 [clear] or 1 [almost clear] in overall disease severity [ODS]). Improvements in week 1 ODS and pruritus were predictive of week 4 treatment success. Subjects who had ODS or pruritus scores of moderate or better at week 1 tended to be treatment successes at week 4 whereas no relationship between week 1 scores and week 4 treatment success was observed for those treated with vehicle spray. The results of this post hoc analysis indicate that early improvement correlates to treatment success.
authors.forename: Steven R
authors.initials: SR
authors.lastname: Feldman
authors.forename: Warren
authors.initials: W
authors.lastname: Winkelman
authors.forename: Eric
authors.initials: E
authors.lastname: Baum
authors.forename: Norman
authors.initials: N
authors.lastname: Preston
mesh_terms: D000279:Administration, Cutaneous; D002990:Clobetasol / Q000008:administration & dosage / Q000627:therapeutic use*; D003879:Dermatologic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D004311:Double-Blind Method; D005938:Glucocorticoids / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D011537:Pruritus / Q000188:drug therapy / Q000209:etiology; D011565:Psoriasis / Q000188:drug therapy* / Q000473:pathology; D012720:Severity of Illness Index; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D003879:Dermatologic Agents; D005938:Glucocorticoids; D002990:Clobetasol